Clinical Trial Update: TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants [Phase 1]

View source ↗

Summary

Phase 1 trial update for TAK-653 in healthy participants completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Depressive Disorder

Drugs mentioned

• TAK-653 (TAK-653)

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Depressive Disorder | Phase 1 | Status: COMPLETED | Results posted: 2019-02-08